A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
← catalyst calendarNCT07520162 · readout in 560 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
230estimated
Sites
39
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-24 | actual | When the study began enrolling |
| Primary completion | 2028-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-07 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyps
Intervention
- Drug: Tezepelumab — also filed as TEZSPIRE®
Primary outcomes
what the primary-completion date above is the date OFTo describe changes from baseline in nasal polyp score (NPS)
measured baseline-week24
To describe changes from baseline in participant-reported nasal congestion as evaluated by nasal congestion score (NCS)
measured baseline-week24
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed